...
首页> 外文期刊>Annals of Surgical Innovation and Research >Feasibility of breast conservation after neoadjuvant taxene based chemotherapy in locally advanced breast cancer: a Prospective Phase I trial
【24h】

Feasibility of breast conservation after neoadjuvant taxene based chemotherapy in locally advanced breast cancer: a Prospective Phase I trial

机译:在局部晚期乳腺癌中,以新辅助紫杉醇为基础的化疗后进行乳房保护的可行性:一项前瞻性I期试验

获取原文
           

摘要

Background Neoadjuvant chemotherapy is the standard care for locally advanced breast cancer. Our study aimed at evaluating the feasibility of breast conversation surgery (BCS) after neoadjuvant chemotherapy. Patients and methods Forty five patients had stage IIB (except those with T2N1 disease) and stage IIIA were selected to 3 cycles taxane-based neoadjuvant chemotherapy. Patient who had tumours ≤5 cm underwent a tentative BCS while patients who had tumour size >5 cm underwent radical surgery. Negative margin is essential for BCS. Adjuvant chemotherapy and 3-D radiotherapy ± hormonal treatment were given to all patients. Results Thirty four patients had BCS. Response to chemotherapy was the only statistically significant factor which influences the BCS. Incidence of local recurrence was 5.9% for patients who had BCS at a median follow up 24 months. Conclusion Breast conservation is feasible in selected cases of locally advanced, non metastatic cancer breast. We recommend that patients who have tumour size ≤4 cm after chemotherapy are the best candidates for BCS.
机译:背景技术新辅助化疗是局部晚期乳腺癌的标准治疗方法。我们的研究旨在评估新辅助化疗后乳房对话手术(BCS)的可行性。患者和方法45例IIB期患者(患有T2N1疾病的患者除外),并且将IIIA期患者选择以紫杉烷为基础的3周期新辅助化疗。肿瘤≤5cm的患者接受了初步的BCS,而肿瘤尺寸> 5 cm的患者则接受了根治性手术。负边距对于BCS至关重要。所有患者均接受辅助化疗和3D放疗±激素治疗。结果34例患者患有BCS。对化疗的反应是影响BCS的唯一统计学上显着的因素。中位随访24个月的BCS患者的局部复发率为5.9%。结论在某些局部晚期非转移性乳腺癌患者中,保乳是可行的。我们建议化疗后肿瘤大小≤4cm的患者是最佳的BCS候选人。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号